Recent News
On January 7, 2026, Cityblock Health and Meridian Health Plan of Illinois, a Centene company, announced a partnership to deliver community-based care to 10,000 Medicaid members across 17 Illinois counties. In December 2025 Centene signed a definitive agreement to divest the remaining Magellan Health businesses and recorded related impairment charges; the company also reported a series of November contributions by Centene subsidiaries and the Centene Foundation to local food banks and community organizations.
Technical Analysis
ADX / DI+ / DI-: ADX at 22.73 indicates an emerging trend strength; both directional indicators trace a reversal pattern (DI+ dip-and-reverse; DI- peak-and-reverse), which together point to a bullish directional shift after prior selling pressure.
MACD: MACD sits at -0.50 with a dip-and-reversal pattern while the signal line sits at -0.35; momentum has started to recover, but MACD remains below its signal line, tempering conviction in sustained bullish momentum until a crossover occurs.
MRO (Momentum/Regression Oscillator): MRO equals -21.52 (negative), indicating the price sits below the modeled target and implies upward potential as the oscillator works back toward zero; the dip-and-reversal in MRO aligns with improving momentum.
RSI: RSI at 54.24 with a dip-and-reverse indicates a mid-range reading that has resumed upward movement, consistent with room for additional near-term gains without being overbought.
Price Vs Moving Averages & Ichimoku: The last close of $43.07 trades above the 20-day average ($40.98), 50-day average ($42.05) and 200-day average ($40.04); the price sits above the Ichimoku cloud (Senkou A $42.26 / Senkou B $39.88), which supports a constructive near-term price bias while volatility remains muted (42‑day volatility 3%).
Bollinger Bands & Volume Context: Price near $43 sits between the 1x and 2x upper Bollinger bands ($43.04 / $45.10) while recent volume of ~4.6M remains below multi-month averages, suggesting follow-through will require renewed participation.
Fundamental Analysis
Earnings & Guidance Context: Reported EPS (actual) of -$1.19 versus estimate -$1.22 produced an EPS surprise of +2.46%. Forward EPS stands at $1.03 with a forward P/E of 37.67. WMDST values the stock as under-valued.
Profitability & Growth Metrics: Reported earnings growth metrics vary by period: the provided earnings growth measure reads -338.00% while year-over-year earnings growth shows +567.76%; quarter-over-quarter earnings growth equals -18.06%. Revenue growth reads 0.0% with QoQ and YoY fields at -100.0%, indicating flat-to-declining top-line comparisons in the supplied intervals.
Valuation Multiples: Trailing P/E shows negative -34.63 due to the recent loss; forward P/E of 37.67 sits below the industry peer mean forward P/E of 53.71 and below the peer median of 51.05, while PEG stands at 0.102 with the industry peer mean PEG near 0.194—both metrics indicate forward earnings expectations priced more cheaply versus peer averages.
Capital & Cash: Invested capital reads $-1,654,000,000 and reported cash-flow metrics show zero in the provided cash-flow fields; cost of debt equals 0.961%. These inputs, combined with elevated health benefits ratio pressures reported in the 2025 results, frame ongoing cash deployment and liability management priorities.
Comparisons To Peer Benchmarks: Relative to the industry peer mean for earnings growth (approximately -11.74%) and peer median (approximately -5.27%), the provided earnings-growth figure stands materially lower; use these peer benchmarks only as context for the supplied company metrics.
Valuation Note: WMDST’s under-valued determination reflects forward earnings power (forward EPS $1.03) and a forward P/E below peer mean and median while accounting for recent impairment and divestiture items disclosed in late 2025.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-12-31 |
| REPORT DATE: | 2026-02-06 |
| NEXT REPORT DATE: | 2026-05-08 |
| CASH FLOW | Begin Period Cash Flow | — |
| Operating Cash Flow | — | |
| Capital Expenditures | — | |
| Change In Working Capital | — | |
| Dividends Paid | — | |
| Cash Flow Delta | — | |
| End Period Cash Flow | — | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | — | |
| Forward Revenue | — | |
| COSTS | ||
| Cost Of Revenue | — | |
| Depreciation | — | |
| Depreciation and Amortization | — | |
| Research and Development | — | |
| Total Operating Expenses | — | |
| PROFITABILITY | ||
| Gross Profit | — | |
| EBITDA | — | |
| EBIT | — | |
| Operating Income | — | |
| Interest Income | — | |
| Interest Expense | — | |
| Net Interest Income | — | |
| Income Before Tax | — | |
| Tax Provision | — | |
| Tax Rate | — | |
| Net Income | — | |
| Net Income From Continuing Operations | — | |
| EARNINGS | ||
| EPS Estimate | $ -1.22 | |
| EPS Actual | $ -1.19 | |
| EPS Difference | $ 0.03 | |
| EPS Surprise | 2.459 % | |
| Forward EPS | $ 1.03 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | — | |
| Intangible Assets | — | |
| Net Tangible Assets | — | |
| Total Current Assets | — | |
| Cash and Short-Term Investments | — | |
| Cash | — | |
| Net Receivables | — | |
| Inventory | — | |
| Long-Term Investments | — | |
| LIABILITIES | ||
| Accounts Payable | — | |
| Short-Term Debt | — | |
| Total Current Liabilities | — | |
| Net Debt | — | |
| Total Debt | — | |
| Total Liabilities | — | |
| EQUITY | ||
| Total Equity | — | |
| Retained Earnings | — | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | — | |
| Shares Outstanding | — | |
| Revenue Per-Share | — | |
| VALUATION | Market Capitalization | — |
| Enterprise Value | — | |
| Enterprise Multiple | — | |
| Enterprise Multiple QoQ | — | |
| Enterprise Multiple YoY | — | |
| Enterprise Multiple IPRWA | — | |
| EV/R | — | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | — | |
| Asset To Liability | — | |
| Debt To Capital | — | |
| Debt To Assets | — | |
| Debt To Assets QoQ | — | |
| Debt To Assets YoY | — | |
| Debt To Assets IPRWA | — | |
| Debt To Equity | — | |
| Debt To Equity QoQ | — | |
| Debt To Equity YoY | — | |
| Debt To Equity IPRWA | — | |
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | — | |
| Price To Book QoQ | — | |
| Price To Book YoY | — | |
| Price To Book IPRWA | — | |
| Price To Earnings (P/E) | -34.628 | |
| Price To Earnings QoQ | -149.448 % | |
| Price To Earnings YoY | -143.95 % | |
| Price To Earnings IPRWA | high: 104.977 mean: 77.86 median: 67.666 low: 33.87 CNC: -34.628 |
|
| PE/G Ratio | 0.102 | |
| Price To Sales (P/S) | — | |
| Price To Sales QoQ | — | |
| Price To Sales YoY | — | |
| Price To Sales IPRWA | — | |
| FORWARD MULTIPLES | ||
| Forward P/E | 37.668 | |
| Forward PE/G | -0.111 | |
| Forward P/S | — | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | — | |
| ASSET & SALES | ||
| Asset Turnover Ratio | — | |
| Asset Turnover Ratio QoQ | — | |
| Asset Turnover Ratio YoY | — | |
| Asset Turnover Ratio IPRWA | — | |
| Receivables Turnover | — | |
| Receivables Turnover Ratio QoQ | — | |
| Receivables Turnover Ratio YoY | — | |
| Receivables Turnover Ratio IPRWA | — | |
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | — | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | — | |
| Cash Conversion Cycle Days QoQ | — | |
| Cash Conversion Cycle Days YoY | — | |
| Cash Conversion Cycle Days IPRWA | high: 33.528 CNC: 0 mean: -1.551 median: -7.057 low: -17.884 |
|
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | — | |
| CapEx To Revenue | — | |
| CapEx To Depreciation | — | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | — | |
| Net Invested Capital | — | |
| Invested Capital | $ -1.65 B | |
| Net Tangible Assets | — | |
| Net Working Capital | — | |
| LIQUIDITY | ||
| Cash Ratio | — | |
| Current Ratio | — | |
| Current Ratio QoQ | — | |
| Current Ratio YoY | — | |
| Current Ratio IPRWA | — | |
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | — | |
| Cost Of Debt | 0.961 % | |
| Interest Coverage Ratio | — | |
| Interest Coverage Ratio QoQ | — | |
| Interest Coverage Ratio YoY | — | |
| Interest Coverage Ratio IPRWA | — | |
| Operating Cash Flow Ratio | — | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | — | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | — | |
| Revenue Growth | 0.0 % | |
| Revenue Growth QoQ | -100.0 % | |
| Revenue Growth YoY | -100.0 % | |
| Revenue Growth IPRWA | high: 5.835 % median: 2.743 % mean: 2.385 % CNC: 0.0 % low: -1.677 % |
|
| Earnings Growth | -338.0 % | |
| Earnings Growth QoQ | -18.061 % | |
| Earnings Growth YoY | 567.76 % | |
| Earnings Growth IPRWA | high: 40.152 % median: -5.274 % mean: -11.737 % low: -44.776 % CNC: -338.0 % |
|
| MARGINS | ||
| Gross Margin | — | |
| Gross Margin QoQ | — | |
| Gross Margin YoY | — | |
| Gross Margin IPRWA | — | |
| EBIT Margin | — | |
| EBIT Margin QoQ | — | |
| EBIT Margin YoY | — | |
| EBIT Margin IPRWA | — | |
| Return On Sales (ROS) | — | |
| Return On Sales QoQ | — | |
| Return On Sales YoY | — | |
| Return On Sales IPRWA | — | |
| CASH FLOW | ||
| Free Cash Flow (FCF) | — | |
| Free Cash Flow Yield | — | |
| Free Cash Flow Yield QoQ | — | |
| Free Cash Flow Yield YoY | — | |
| Free Cash Flow Yield IPRWA | — | |
| Free Cash Growth | — | |
| Free Cash Growth QoQ | — | |
| Free Cash Growth YoY | — | |
| Free Cash Growth IPRWA | — | |
| Free Cash To Net Income | — | |
| Cash Flow Margin | 0.0 % | |
| Cash Flow To Earnings | 0.0 | |
| VALUE & RETURNS | ||
| Economic Value Added | — | |
| Return On Assets (ROA) | — | |
| Return On Assets QoQ | — | |
| Return On Assets YoY | — | |
| Return On Assets IPRWA | — | |
| Return On Capital Employed (ROCE) | — | |
| Return On Equity (ROE) | — | |
| Return On Equity QoQ | — | |
| Return On Equity YoY | — | |
| Return On Equity IPRWA | — | |
| DuPont ROE | — | |
| Return On Invested Capital (ROIC) | — | |
| Return On Invested Capital QoQ | — | |
| Return On Invested Capital YoY | — | |
| Return On Invested Capital IPRWA | — | |